Hear community perspectives on topics ranging from navigating a diagnosis to reflecting on clinical trial experiences.
It was May of 2020. What started off as a virus we were observing from the US wreak havoc first in Asia, then Europe, was now firmly taking hold locally. The two-week home school period, turned into two months and families were thrown into the impossible transition of figuring out how to work from our living rooms and support our kids’ education through endless Zoom meetings and classes. Life as we knew it was on hold…seemingly endlessly…and many were crippled with fear of the toll COVID-19 could have on us and the world we live in. But something was about to disrupt our lives in a far more meaningful and personal and terrifying way than any global pandemic ever could.
May is Ehlers Danlos Syndrome (EDS) Awareness Month, so today I’m sharing my experience with the condition. I have hypermobility type EDS (hEDS), but there are 12 other types of EDS...
Unlike traditional methods for developing therapeutics for common and (relatively) rare diseases, ultra-rare disease drug development requires a different approach and mechanism in light of a limited ability to commercialize and even reach BLA/NDA approval once clinical trials are complete....